|June 10, 2014|
|16:05 EDT||RHHBY||Health Canada approves Roche's HPV test for screening cervical cancer |
Roche announced that Health Canada approved the cobas 4800 HPV Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche has also launched the fully automated CINtec PLUS test to improve the detection and early intervention of pre-cancerous cervical disease. The Health Canada approved CINtec PLUS cytology test helps identify women with high-grade pre-cancerous cervical lesions who need immediate colposcopy. Roche's portfolio of cervical cancer screening products provides the most comprehensive strategies for cervical cancer prevention and treatment. The cobas 4800 HPV Test provides both pooled high-risk HPV DNA results and individual detection of HPV 16 and HPV 18, the two types responsible for about 70% of cervical cancer. Health Canada's decision to approve the expanded use for the cobas 4800 HPV Test was based on results from the landmark ATHENA trial, which enrolled more than 47,000 women. The study demonstrated that one in four women who are HPV 16 positive will have cervical disease within three years and that nearly 1 in 7 women with normal Pap cytology who were HPV 16 positive actually had high-grade cervical disease that was missed by cytology.
News For RHHBY From The Last 14 Days
|April 17, 2015|
|05:32 EDT||RHHBY||Accelerate Diagnostics appoints Pete Bantock to Chief Culture Officer|
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
|April 16, 2015|
|08:04 EDT||RHHBY||Roche granted orphan status for lymphoma treatment|
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
|April 14, 2015|
|06:30 EDT||RHHBY||Roche to seek to have cancer drug tested in 11 trials in 2015, Reuters says|
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
|April 13, 2015|
|10:01 EDT||RHHBY||Roche acquires CAPP Medical|
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
|April 8, 2015|
|15:19 EDT||RHHBY||Roche says receives European approval for Avastin plus chemotherapy|
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
|April 7, 2015|
|07:14 EDT||RHHBY||Eyeforpharma to hold a summit|
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.